VIRVir Biotechnology, Inc.

$1B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$813M+269915.6% YoY

Gross Profit

$628M77.2% margin

Operating Income

$572M70.3% margin

Net Income

$525M64.6% margin

EPS (Diluted)

$3.92

QoQ Revenue Growth

+684.4%

Cash Flow

Operating Cash Flow

$8M

Free Cash Flow

-$5M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$522M

Stockholders' Equity

$1.4B

Cash & Equivalents

$348M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$813M	$301,000	+269915.6%
Gross Profit	$628M	$301,000	+208381.4%
Operating Income	$572M	-$108M	+627.4%
Net Income	$525M	-$106M	+597.2%

Revenue Segments

Collaboration Revenue

$809M100%

Contract Revenue

$293,0000%

VIR Q4 2021 Earnings — Vir Biotechnology, Inc. Revenue & Financial Results | Market Cap Arena